Top ▲

Inflammatory myofibroblastic tumor

Disease ID:495
Name:Inflammatory myofibroblastic tumor
Associated with:1 target
1 immuno-relevant ligand
Database Links
Orphanet: ORPHA178342

Targets

ALK receptor tyrosine kinase
Ligand interactions: 
Ligand Comments
crizotinib
Crizotinib is an approved drug for the treatment of unresectable, recurrent, or refractory ALK+ve inflammatory myofibroblastic tumours

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
crizotinib
Immuno Disease Comments: Crizotinib is an approved drug for the treatment of unresectable, recurrent, or refractory ALK+ve inflammatory myofibroblastic tumours
Clinical Use: Crizotinib was originally approved for treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung carcinomas (NSCLC).
In March 2016, the US FDA expanded marketing authorisation to include treatment of patients with ROS1-positive metastatic NSCLC. Clinical trials for anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumours are ongoing.
In mid-2018, the FDA granted breakthrough designations for Xalkori as a treatment for NSCLC with MET exon 14 alterations (and with disease progression on or after platinum-based chemotherapy), and as a treatment for ALK-positive relapsed/refractory systemic anaplastic large cell lymphoma. Approval was expanded further in July 2022, when crizotinib was granted FDA approval as a treatment for unresectable, recurrent, or refractory inflammatory ALK-positive myofibroblastic tumours. | View clinical data
Bioactivity Comments: The (S)-enantiomer () is considerably less potent than the (R)-enantiomer against its established protein kinase targets [1]. Interestingly, (S)-crizotinib has been reported to inhibit the activity of NUDT1 (P36639) with a Kd of 48nM [1]. NUDT1 is an antimutagenic enzyme involved in the effective elimination of oxidised nucleotides (induced by oxidative stress, for example), thus preventing their incorporation into DNA. At this target the (R)-enantiomer is the less potent enantiomer (Kd 781nM). This highlights the necessity that drug compounds be steroespecifically pure when there is a pharmacological difference in activity between stereoisomers (ie they exhibit distinct molecular mechanisms of action), as enantiomerically impure mixtures may result in off-target effects.
A number of chemical suppliers and other submitters to online chemistry databases specify the non-stereoisomeric molecule depicted in PubChem CID 11597571. | View biological activity

References

Show »

1. Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Göktürk C, Sanjiv K, Strömberg K et al.. (2014) Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature, 508 (7495): 222-7. [PMID:24695225]